StimulusBio @StimulusBio

StimulusBio is heading to the International Society for Cell & Gene Therapy Annual Meeting in Dublin this May 6th - 9th! 📍 Poster #982 📅 May 6, Elevator Pitch Session & 📅 May 7, Poster Presentation

Excited to share that StimulusBio will be presenting at the Cell and Gene Meeting on the Med in Rome next week! Join Mimi Healy, Ph.D., for a company presentation: 📅 April 29 🕓 4:15 PM 📍 Salone dei Cavalieri, Section 1

Don't miss our CEO, Mimi Healy, at The Next Chapter in Blood Banking. She will be joining an esteemed panel from NALHE and Gulf Coast Blood to discuss research opportunities in blood banking. Date: Thursday, February 12, 2026 Time: 6:00 PM Location: TMCi Innovation Factory

We're happy to have Ayo back in the StimulusBio lab. In her summer internship, she helped us develop our sbPCI technology. And now with a fresh PhD in hand, she will be applying her extensive knowledge in cell & gene therapy to further improve our product offerings.

Our goal in 2026? Help C&GT researchers and tools providers lower the cost and time of manufacturing. Our proprietary sbPCI technology provides a more targeted and customizable method for cell expansion and activation. #CGT #Manufacturing #Science #Research

sbPCI™ mimics the natural immune synapse, offering control over density, distribution, and composition—a capability that supports next-generation potency assays and patient-specific therapies. #Immunology #PrecisionMedicine #StimulusBio

Help us welcome Javiera Bravo-Alegria, Ph.D., to the StimulusBio team! Javiera brings over a decade of experience in cell therapy, immunology, cancer research, and pharmaceutical/CDMO operations.

From PBMCs to robust T cell expansion — no isolation required. CellPilot™ delivers consistent expansion across donors and formulations, outperforming gold-standard methods. All without T cell isolation. 📄 Read our website's whitepaper #CellTherapy #CGT #StimulusBio

Need to enrich your cultures for CD8+ T cells? ✅ Our product does that. Preferential expansion that is efficient, scalable, and built for CGT workflows. Learn how CellPilot fits into your pipeline. #CD8Selection #TCellTech #StimulusBio

StimulusBio’s Programmable Cellular Interface (sbPCI™) addresses these challenges by enabling modular, rapid functionalization of immune cells. Researchers can design and deploy tailored configurations in as little as two weeks.

keyboard_arrow_left Previous keyboard_arrow_right Next

Cell and gene therapy (CGT) holds immense promise for treating cancer and rare diseases, but the industry faces a major challenge: traditional immune cell engineering workflows take 6–9 months and cost over $500K.

The 2025 @NobelPrize in Physiology or Medicine was awarded for the discovery of regulatory T cells (Tregs) and their role in maintaining immune tolerance. See StimulusBio programmable cellular interface (sbPCI) 🧬 #Immunotherapy #CellTherapy #NobelPrize #CGT

🎯 @sitcancer bound! StimulusBio will be there with: ✅ 3 posters ✅ 1 booth ✅ A whole lot of science Let’s talk strategy, science, and how we can help you accelerate your CGT programs. Stop by booth #928! #SITC #SITC2025 #Immunology #Science

We help define the product, milestones, and data that resonate with strategic partners, because credibility isn’t built in a single meeting; it’s built across every milestone. #Biotech #BusinessDevelopment #Science

We’ll be at Meeting on the Mesa; let’s connect! Let’s talk strategy, science, and how we can help you accelerate your CGT programs. @regenerativerm #Mesa2025 #CGT #Networking #StimulusBio #CGMesa25 #RegenerativeMedicine #AdvancedTherapies

At StimulusBio, our mission is simple: Enable researchers to do their best work through data-driven strategy and rigorous science. Let's build a future for your CGT workflow together. #ResearchExcellence #CGTTools #StimulusBio

From improving T cell workflows to the development of the next generation of assay standards, StimulusBio builds tools that take researchers to the next level. Check out how our science is shaping the future of #CGT & #diagnostics.

StimulusBio to present at Meeting on the Mesa! Our CEO, Mimi Healy, PhD, can't wait to share how upcoming StimulusBio products will ignite potential for CGT scientists. See you in Phoenix! @alliancerm #CGT #StimulusBio #CGMesa25 #RegenerativeMedicine #AdvancedTherapies

🎷StimulusBio is Ready to Jazz Up ISCT 2025! 🎷 🧬 Join us as we showcase our groundbreaking research with Poster #967 titled "Narrowing the Immunotherapy Window Through Use of a Programmable Cellular Interface." 🧬 #ISCT2025 #StimulusBio #Immunotherapy #CellularInterface

Most life science products fail between 75% to 90%. But not because of the science. The reasons are surprisingly consistent: unclear positioning, misaligned teams, and flawed market assumptions. #Biotech #ProductDev #TranslationalScience